Bahl & Gaynor Inc Novartis Ag Transaction History

Bahl & Gaynor Inc

$17.9 Billion
Q2 2024

A detailed history of Bahl & Gaynor Inc transactions in Novartis Ag stock. As of the latest transaction made, Bahl & Gaynor Inc holds 102,195 shares of NVS stock, worth $11.8 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

102,195

Previous 103,010 0.79%

Holding current value

$11.8 Million

Previous $9.96 Million 9.18%

% of portfolio

0.06%

Previous 0.06%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$92.57 - $107.37 $75,444 - $87,506	-815 Reduced 0.79%	102,195 $10.9 Million
Q1 2024 May 10, 2024	SELL	$95.27 - $108.47 $76,978 - $87,643	-808 Reduced 0.78%	103,010 $9.96 Million
Q4 2023 Feb 02, 2024	SELL	$92.27 - $101.54 $25,005 - $27,517	-271 Reduced 0.26%	103,818 $10.5 Million
Q3 2023 Nov 03, 2023	SELL	$94.73 - $105.13 $210,205 - $233,283	-2,219 Reduced 2.09%	104,089 $10.6 Million
Q2 2023 Aug 14, 2023	BUY	$92.52 - $104.91 $277 - $314	3 Added 0.0%	106,308 $10.7 Million
Q1 2023 May 03, 2023	SELL	$80.03 - $92.81 $95,715 - $111,000	-1,196 Reduced 1.11%	106,305 $9.78 Million
Q4 2022 Feb 10, 2023	BUY	$75.55 - $92.52 $52,733 - $64,578	698 Added 0.65%	107,501 $9.75 Million
Q3 2022 Nov 14, 2022	SELL	$74.61 - $87.26 $567,782 - $664,048	-7,610 Reduced 6.65%	106,803 $8.12 Million
Q2 2022 Aug 08, 2022	SELL	$80.52 - $93.75 $601,484 - $700,312	-7,470 Reduced 6.13%	114,413 $9.67 Million
Q1 2022 May 12, 2022	SELL	$80.11 - $90.62 $808,950 - $915,080	-10,098 Reduced 7.65%	121,883 $10.7 Million
Q4 2021 Feb 10, 2022	SELL	$79.7 - $88.13 $605,959 - $670,052	-7,603 Reduced 5.45%	131,981 $11.5 Million
Q3 2021 Nov 15, 2021	SELL	$81.78 - $95.14 $130,193 - $151,462	-1,592 Reduced 1.13%	139,584 $11.4 Million
Q2 2021 Aug 06, 2021	SELL	$85.24 - $94.15 $1.64 Million - $1.81 Million	-19,234 Reduced 11.99%	141,176 $12.9 Million
Q1 2021 May 11, 2021	SELL	$83.5 - $98.47 $197,060 - $232,389	-2,360 Reduced 1.45%	160,410 $13.7 Million
Q4 2020 Feb 02, 2021	SELL	$78.07 - $94.43 $172,846 - $209,068	-2,214 Reduced 1.34%	162,770 $15.4 Million
Q3 2020 Nov 12, 2020	SELL	$82.14 - $91.0 $425,238 - $471,107	-5,177 Reduced 3.04%	164,984 $14.3 Million
Q2 2020 Aug 13, 2020	SELL	$80.93 - $91.1 $353,906 - $398,380	-4,373 Reduced 2.51%	170,161 $14.9 Million
Q1 2020 May 26, 2020	BUY	$70.67 - $99.01 $12.3 Million - $17.3 Million	174,534 New	174,534 $14.4 Million
Q1 2020 May 15, 2020	SELL	$70.67 - $99.01 $13.4 Million - $18.7 Million	-189,238 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$84.35 - $95.37 $386,154 - $436,603	-4,578 Reduced 2.36%	189,238 $17.9 Million
Q3 2019 Nov 14, 2019	SELL	$85.54 - $94.26 $8,040 - $8,860	-94 Reduced 0.05%	193,816 $16.8 Million
Q2 2019 Aug 12, 2019	SELL	$75.4 - $92.8 $863,782 - $1.06 Million	-11,456 Reduced 5.58%	193,910 $17.7 Million
Q1 2019 May 13, 2019	SELL	$75.32 - $86.15 $263,620 - $301,525	-3,500 Reduced 1.68%	205,366 $19.7 Million
Q4 2018 Feb 12, 2019	SELL	$73.66 - $82.02 $438,129 - $487,854	-5,948 Reduced 2.77%	208,866 $17.9 Million
Q3 2018 Nov 09, 2018	SELL	$66.94 - $77.43 $372,788 - $431,207	-5,569 Reduced 2.53%	214,814 $18.5 Million
Q2 2018 Aug 14, 2018	SELL	$64.91 - $73.36 $17.3 Million - $19.6 Million	-266,800 Closed	0 $0
Q1 2018 May 11, 2018	SELL	$70.39 - $84.15 $448,806 - $536,540	-6,376 Reduced 2.33%	266,800 $21.6 Million
Q4 2017 Feb 13, 2018	BUY	$72.33 - $77.64 $14,393 - $15,450	199 Added 0.07%	273,176 $22.9 Million
Q3 2017 Nov 13, 2017	SELL	$74.14 - $77.27 $1.07 Million - $1.12 Million	-14,438 Reduced 5.02%	272,977 $23.4 Million
Q2 2017 Aug 11, 2017	SELL	N/A	-127,018 Reduced 30.65%	287,415 $24 Million
Q2 2017 Aug 10, 2017	BUY	N/A	414,433	414,433 $30.2 Million

Others Institutions Holding NVS

# of Institutions

1,426

Shares Held

138M

Call Options Held

1.48M

Put Options Held

1.54M

View Full List

About NOVARTIS AG

Ticker NVS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,151,000,064
Market Cap $247B
Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...

More about NVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bahl & Gaynor Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bahl & Gaynor Inc with notifications on news.

Account